14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
VTVT vs MTNB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (54.6/100 HOLD vs. 38.9/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. VTVT trades at $16.36 (N/M Forward P/E, -29.8% operating margin) versus MTNB at $0.81 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. VTVT 38.9/100 SELL) and -7.20β · 147% Vol risk profile, whereas VTVT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: VTVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTVT vs MTNB. Trailing 12-month operating profitability (VTVT -29.8% vs MTNB 0.0%) and valuation multiples (VTVT N/M vs MTNB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VTVT vs MTNB Key Questions & Quantitative Answers
As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (54.6/100 HOLD vs. 38.9/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. VTVT trades at $16.36 (N/M Forward P/E, -29.8% operating margin) versus MTNB at $0.81 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. VTVT 38.9/100 SELL) and -7.20β · 147% Vol risk profile, whereas VTVT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VTVT leads the Growth & Scale pillar: VTVT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $37M TTM revenue (20.8% gross margin, -29.8% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VTVT generates $37M in USD-normalized revenue versus N/A for MTNB. In operating R&D and SG&A reinvestment, VTVT deploys 50.6% of Rev ($19M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.
VTVT screens cheaper on headline valuation multiples. VTVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-29.8% EBITDA margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTVT (-10.9% ROE) versus MTNB (-147.5% ROE) capital efficiency.
In options market volatility and institutional positioning, VTVT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.51β · 55% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.